Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case 33% Improvement Relative Risk Case 44% Sainz-Amo et al. Vitamin D for COVID-19 Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Retrospective 211 patients in Spain Lower severe cases (p=0.45) and fewer cases (p=0.23), not stat. sig. Sainz-Amo et al., J. Neurology, doi:10.1007/s00415-020-10272-0 Favors vitamin D Favors control
COVID-19 in Parkinson’s disease: what holds the key?
Sainz-Amo et al., Journal of Neurology, doi:10.1007/s00415-020-10272-0
Sainz-Amo et al., COVID-19 in Parkinson’s disease: what holds the key?, Journal of Neurology, doi:10.1007/s00415-020-10272-0
Oct 2020   Source   PDF  
  All Studies   Meta
Case control study with 39 COVID+ and 172 COVID- Parkinson's disease patients in Spain, showing positive and severe cases being less likely to use vitamin D supplementation compared to negative or mild/negative cases respectively. These differences were not statistically significant.
risk of severe case, 32.7% lower, OR 0.67, p = 0.45, treatment 5 of 29 (17.2%) cases, 43 of 182 (23.6%) controls, NNT 23, case control OR.
risk of case, 43.7% lower, OR 0.56, p = 0.23, treatment 6 of 39 (15.4%) cases, 42 of 172 (24.4%) controls, NNT 13, case control OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sainz-Amo et al., 24 Oct 2020, retrospective, Spain, peer-reviewed, mean age 74.5, 13 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Journal of Neurology (2021) 268:2666–2670 ORIGINAL COMMUNICATION COVID‑19 in Parkinson’s disease: what holds the key? R. Sainz‑Amo1 · B. Baena‑Álvarez1 · I. Pareés1 · G. Sánchez‑Díez1 · P. Pérez‑Torre1 · J. L. López‑Sendón1 · S. Fanjul‑Arbos1 · E. Monreal1 · I. Corral‑Corral1 · N. García‑Barragán1 · J. C. Martínez‑Castrillo1 · A. Fasano2,3 · A. Alonso‑Cánovas1 Received: 10 September 2020 / Revised: 4 October 2020 / Accepted: 10 October 2020 / Published online: 24 October 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020 Abstract Introduction Parkinson’s disease (PD) is more frequent in the elderly and increases the risk of respiratory infections. Previous data on PD and SARS-CoV-2 are scarce, suggesting a poor prognosis in advanced disease and second-line therapies. Methods A retrospective case–control study comparing patients with PD and COVID-19 and patients with PD without COVID-19 was conducted during the pandemic period in Spain (March 1st–July 31st 2020) in a tertiary university hospital. Results Thirty-nine (COVID-19 +) and 172 (COVID-19-) PD patients were included. Fifty-nine percent were males in both groups, with similar age (75.9 ± 9.0 COVID-19 + , 73.9 ± 10.0 COVID-19-), disease duration (8.9 ± 6.2 COVID-19 + , 8.5 ± 5.6 COVID-19-) and PD treatments. COVID-19 was mild in 10 (26%), required admission in 21 (54%) and caused death in 8 (21%) patients. Dementia was the only comorbidity more frequent in COVID-19 + patients (36% vs. 14%, p = 0.0013). However, in a multivariate analysis, institutionalization was the only variable associated with COVID-19 + (OR 17.0, 95% CI 5.0–60.0, p < 0.001). When considering severe COVID-19 (admission or death) vs. mild or absent COVID-19, institutionalization, neoplasm, dementia and a lower frequency of dopamine agonists were associated with severe COVID-19. In multivariate analysis, only institutionalization [OR 5.17, 95% CI 1.57–17, p = 0.004] and neoplasm [OR 8.0, 95%CI 1.27–49.8, p = 0.027] remained significantly associated. Conclusion In our experience, institutionalization and oncologic comorbidity, rather than PD-related variables, increased the risk of developing COVID-19, and impacted on its severity. These findings suggest that epidemiologic factors and frailty are key factors for COVID-19 morbidity/mortality in PD. Appropriate preventive strategies should be implemented in institutionalized patients to prevent infection and improve prognosis. Keywords SARS-CoV-2 · COVID-19 · Parkinson · Institutionalization · Comorbidity · Prognosis
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop